WO2011041989A2 - Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular - Google Patents
Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular Download PDFInfo
- Publication number
- WO2011041989A2 WO2011041989A2 PCT/CU2010/000004 CU2010000004W WO2011041989A2 WO 2011041989 A2 WO2011041989 A2 WO 2011041989A2 CU 2010000004 W CU2010000004 W CU 2010000004W WO 2011041989 A2 WO2011041989 A2 WO 2011041989A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- ring
- systems
- activity
- central
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Definitions
- the present invention relates to the chemical branch, the pharmaceutical branch and specifically with regard to obtaining new molecular entities, synthetic variants of diazepines fused to dihydropyridines of the general formula:
- R represents H, alkyl group (preferably alkyl groups of up to 8 straight chain carbon atoms or branched, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, and the chain isomers of all of the above; as well as cyclic alkyls, and substituted alkyls, preferably substituted with halogens; vinyl and vinylsubstituted; and cyclic alkyl chains , preferably the cyclohexyl group.
- R also represents an aryl group (benzyl, naphthyl and substituted naphthyl or anthracil).
- R also represents heteroaryl, substituted heteroaryl, where heteroaryl and substituted heteroaryl preferably refers to furfuryl, furfuryl substituted, pyrrolidyl, substituted pyrrolidyls, thiophenyl, substituted thiophenyl, pyridyl (2-pyridyl, 3-pyridyl and 4-pyridyl), substituted pyridyl, quinolinyl (2-quinolinyl, 3- quinolinyl, 4-quinolinyl), pyrazolyl.
- R represents H, alkyl group, straight or branched chain and alicyclic, preferably with a number of carbon atoms between 1 and 16.
- R ⁇ also represents OR ' where R ' independently represents H, or its salts of Sodium (Na) and Potassium (K); alkyl groups of 1 and up to 24 carbon atoms, straight or branched chains such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl.
- R ' also represents lipid chains derived from mono and polyunsaturated fatty acids of up to 24 carbon atoms.
- R It also represents amino acid residues of the type -NH-CH (R4) -COOH, where R 4 are amino acid residues, preferably valine, phenylalanine, alanine, histidine, Usine, tryptophan, cysteine, leucine, tyrosine, isoleucine, proline and methionine; Rl also represents small peptide chains of between 2 and up to 12 amino acids, obtained by combinations of some of them chosen independently.
- Ri also represents -NHR , where R 5 is a thiazole and substituted thiazole ring, 4-phenylthiazole or 4- substituted phenylthiazole; R 5 also represents a phenyl and substituted phenyl substituent.
- R 2 represents an alkyl or cycloalkyl group; alkyl groups can be straight or branched chain between 1 and up to 16 carbon atoms; groups - (CH 2 ) n-NH2 and groups - (CH 2 ) n-OH, where n is 1 and up to 8.
- cycle A is a 6-membered aromatic ring fused to the diazepine ring and represents a ring of benzene or substituted benzene, forming a benzodiazepine, fused in such a way that it implies a structure and all its positional isomers and all possible tautomers.
- the benzene fused to diazepine represented as ring A, is in turn substituted by one and up to four substituents independently selected from OH, COOH, CH 3 , N0 2 , NH 2 , CHO (formyl group), halogens and combinations thereof .
- cycle A is also a 6-membered heterocyclic ring fused to the diazepine ring and represents a ring of pyridine and substituted pyridine, preferably with halogens.
- the pyridine ring may be fused to the diazepine ring in such a way that it implies a structure and all its possible position isomers and all possible tautomers.
- This new type of compounds can serve as a basis for medications with therapeutic applications in the treatment of anxiety, ischemia, epilepsy, high blood pressure and other cardiovascular, cerebrovascular disorders. neurodegenerative, neuropsychiatric, neurological and others related to the cardiovascular system.
- Compounds of type I, II, III, X, XI and XII are obtained by fusion of a properly substituted 1,4-dihydropyridine derivative, with a disubstituted ortho-diamino compound, ortho-phenylenediamine, ortho-diaminopyridines, r-diaminopyrimidines , to generate tricyclic (I, II, III) and tetracyclic (X, XI and XII) compounds derived from fused diazepines or diazepinones to the 1,4-dihydropyridine derivative.
- the new derivatives are obtained as a racemic modification, when starting from the racemic 1,4-dihydropyridine derivatives, obtained in turn through their synthetic precursors, which are also obtained in the form racemic
- the enantiomers can be resolved and obtained separately, with an enantiomeric excess greater than 90%, and is carried out by enantiomeric resolution of any of the starting intermediates, or by enantiomeric resolution directly in the final product, preferably by enzymatic resolution, with a previous chemical transformation (which is not always necessary) to facilitate the resolution process, and its subsequent transformation to the original structure already resolved. All separate enantiomers were further characterized by measuring their specific rotation.
- Benzodiazepines constituted the first pharmacological entity called privileged structures.
- benzodiazepines act as depressants of the central nervous system (CNS) by inhibitory action of GABA When part of a connected inhibiting bidirectional system between different areas of the CNS.
- CNS central nervous system
- GABA central nervous system
- the novelty of the present invention consists mainly in obtaining a tricyclic or tetracyclic molecular system consisting of a diazepine derivative fused to a DHP ring, with possible application in the treatment of cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric and neurological diseases, as well as the possibility of obtaining them by a simple synthetic process, using as starting material derivatives of 1,4-dihydropyridines.
- EP 1593683 and EP1 157992 describe the production of molecules derived from dihydro-2,3-benzodiazepine as potential anticonvulsants, but employs hydrogen type substituents, alkyl chains and aromatic rings such as phenyl, thienyl, furyl, pyridyl, imidazolyl, benzimidazolyl, benzothiazolyl and pthalazinyl.
- EP-349949 describes benzodiazepine derivatives substituted with heterocyclic groups substituted in turn with aryl, hydroxyl, carboxylic groups.
- US20040157833 discloses pharmaceutical compositions from 1 - (3,4-dimethoxyphenyl) -4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.
- US20020103371 describes benzodiazepine derivatives modulating the GABA receptor, but they do not relate dihydropyridines.
- EP-733634 describes the obtaining of new molecular entities derived from thieno (2,3-B) (1, 5) benzodiazepine.
- EXAMPLE 1 SYNTHESIS OF THE SYNTHETIC INTERMEDIARY 4-ARIL-5-CARBONILACOHOXI- 6-METHYL-2-OXO-l, 2,3,4-TETRAHYDROPIRIDINE USEFUL FOR THE PREPARATION OF TYPE I, II, III COMPOUNDS. METHOD 1.
- EXAMPLE 2 SYNTHESIS OF THE SYNTHETIC INTERMEDIARY DERIVED FROM 4-ARIL-5- CARBONILACOHOXI-6-METHYL-2-OXO-l, 2,3,4-TETRAHYDROPIRIDINE, USEFUL FOR THE PREPARATION OF COMPOUNDS OF TYPE I, II, III, IV , V, VI, VII, XIII, IX, X, XI and XII.
- the 4-aryl-3-carbonyl-alkoxy-2-methyl-6-chloro-5-formyl-1, 4-dihydropyridine derivatives constitute another synthesis intermediate.
- an equimolar amount of phosphorus oxychloride is added at room temperature.
- a solution of the corresponding 4-aryl-5-carbonylakoxy-6-methyl-2-oxo-2,3,4-tetrahydropyridine derivative is added.
- an aqueous solution of sodium acetate is added and stirred for a time 10-30 minutes.
- the organic phase is separated and the solvent is removed in vacuo.
- the solid obtained is recrystallized from ethanol.
- the corresponding derivative of 1,4-dihydropyridine derivative is dissolved in ethanol in a balloon equipped with magnetic stirring.
- the corresponding 1,2-diamine is added to the resulting solution.
- the reaction mixture is stirred at temperatures between 10-78 ° C for a few hours, observing the appearance of a precipitate. It is filtered, and purified by washing with ethanol. For some of the compounds it is necessary to isolate the final products by means of the column chromatography technique.
- EXAMPLE 7 EFFECT OF DIFFERENT SYNTHETIC VARIANTS OF DIAZEPINES FUSED TO DIHYDROPIRIDINS ON EXPLORATORY BEHAVIOR IN MOUSES.
- the open field trial has been a widely used test in the evaluation of drugs with a sedative effect, in which the number of animal stops and / or crossings through the central area of an open field is quantified; These behaviors are indicative of rodent exploratory behavior. Sedative drugs decrease their exploratory activity.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012532450A JP2013507329A (ja) | 2009-10-09 | 2010-10-08 | 脈管系および中枢神経系に作用する三環系化合物および四環系化合物 |
CA2777209A CA2777209C (en) | 2009-10-09 | 2010-10-08 | Tricyclic and tetracyclic systems with activity on the central-nervous and vascular systems |
US13/500,983 US9315497B2 (en) | 2009-10-09 | 2010-10-08 | Tricyclic and tetracyclic systems with activity on the central nervous and vascular systems |
CN2010800556597A CN102656171A (zh) | 2009-10-09 | 2010-10-08 | 对血管系统和中枢神经系统起作用的三环和四环系统 |
EP10821598.9A EP2487174A4 (en) | 2009-10-09 | 2010-10-08 | TRICYCLIC AND TETRACYCLIC SYSTEMS WITH EFFECT ON THE CENTRAL NERVOUS AND VACUUM SYSTEM |
ZA2012/03295A ZA201203295B (en) | 2009-10-09 | 2012-05-07 | Tricyclic and tetracyclic systems with activity on the central-nervous and vascular systems |
US14/282,111 US10138231B2 (en) | 2009-10-09 | 2014-05-20 | Tricyclic and tetracyclic systems acting upon the vascular and central nervous systems |
US16/171,046 US20190092769A1 (en) | 2009-10-09 | 2018-10-25 | Tricyclic and tetracyclic systems acting upon the vascular and central nervous systems |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CUPCT/CU2009/000172 | 2009-10-09 | ||
CU20090172A CU20090172A6 (es) | 2009-10-09 | 2009-10-09 | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/500,983 A-371-Of-International US9315497B2 (en) | 2009-10-09 | 2010-10-08 | Tricyclic and tetracyclic systems with activity on the central nervous and vascular systems |
US14/282,111 Continuation-In-Part US10138231B2 (en) | 2009-10-09 | 2014-05-20 | Tricyclic and tetracyclic systems acting upon the vascular and central nervous systems |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011041989A2 true WO2011041989A2 (es) | 2011-04-14 |
WO2011041989A3 WO2011041989A3 (es) | 2011-09-15 |
Family
ID=45000047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2010/000004 WO2011041989A2 (es) | 2009-10-09 | 2010-10-08 | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular |
Country Status (9)
Country | Link |
---|---|
US (3) | US9315497B2 (es) |
EP (1) | EP2487174A4 (es) |
JP (1) | JP2013507329A (es) |
KR (1) | KR20120093940A (es) |
CN (1) | CN102656171A (es) |
CA (1) | CA2777209C (es) |
CU (1) | CU20090172A6 (es) |
WO (1) | WO2011041989A2 (es) |
ZA (1) | ZA201203295B (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9284331B2 (en) | 2012-08-23 | 2016-03-15 | Novartis Ag | Diazepinone derivatives |
WO2021139843A2 (es) | 2019-12-26 | 2021-07-15 | Centro de Investigación Y Desarrollo de Medicamentos CIDEM | Composición y método de tratamiento para simultáneamente incrementar la eficacia analgésica de los opioides y reducir su poder adictivo |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
CU20160058A7 (es) * | 2016-05-04 | 2017-12-08 | Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular |
WO2022055168A1 (ko) * | 2020-09-09 | 2022-03-17 | 서울대학교산학협력단 | 신규 피리미도디아제핀 유도체 및 이의 용도 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0349949A2 (en) | 1988-07-07 | 1990-01-10 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
EP0491218A1 (en) | 1990-12-17 | 1992-06-24 | F. Hoffmann-La Roche Ag | Benzodiazepinones |
EP0558104A1 (en) | 1992-01-21 | 1993-09-01 | GLAXO S.p.A. | 1,5-Benzodiazepine derivatives and their use in medicine |
EP0733634A1 (en) | 1995-03-24 | 1996-09-25 | Eli Lilly And Company | Process for preparing a thieno(2,3-B)(1,5) benzodiazepine derivative |
US5610158A (en) | 1992-02-13 | 1997-03-11 | The Upjohn Company | 4-oxo- and 4H-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents |
US5658901A (en) | 1994-08-18 | 1997-08-19 | Merck & Co., Inc. | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines |
EP1157992A1 (en) | 1994-08-31 | 2001-11-28 | Eli Lilly And Company | Dihydro-2,3-Benzodiazepine derivatives |
US20020103371A1 (en) | 2000-11-16 | 2002-08-01 | Raffaello Masciadri | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives |
US20040157833A1 (en) | 2002-12-03 | 2004-08-12 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1- (3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3780047A (en) * | 1972-07-05 | 1973-12-18 | Squibb & Sons Inc | Derivatives of pyrazolo(3',4'-2,3)pyrido(4,5-e)b-benzo-1,5-diazepines |
US4012373A (en) * | 1972-09-22 | 1977-03-15 | E. R. Squibb & Sons, Inc. | Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones |
US5571809A (en) * | 1989-04-20 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | The treatment of HIV-1 infection using certain pyridodiazepines |
EP0498290B1 (en) * | 1991-02-07 | 1996-09-18 | Boehringer Ingelheim Pharmaceuticals Inc. | Pyridobenzodiazepines, dipyrido [3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection |
GB9201180D0 (en) | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
-
2009
- 2009-10-09 CU CU20090172A patent/CU20090172A6/es active IP Right Grant
-
2010
- 2010-10-08 US US13/500,983 patent/US9315497B2/en not_active Expired - Fee Related
- 2010-10-08 CA CA2777209A patent/CA2777209C/en active Active
- 2010-10-08 EP EP10821598.9A patent/EP2487174A4/en not_active Withdrawn
- 2010-10-08 KR KR1020127011917A patent/KR20120093940A/ko not_active Application Discontinuation
- 2010-10-08 JP JP2012532450A patent/JP2013507329A/ja active Pending
- 2010-10-08 CN CN2010800556597A patent/CN102656171A/zh active Pending
- 2010-10-08 WO PCT/CU2010/000004 patent/WO2011041989A2/es active Application Filing
-
2012
- 2012-05-07 ZA ZA2012/03295A patent/ZA201203295B/en unknown
-
2014
- 2014-05-20 US US14/282,111 patent/US10138231B2/en active Active
-
2018
- 2018-10-25 US US16/171,046 patent/US20190092769A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0349949A2 (en) | 1988-07-07 | 1990-01-10 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
EP0491218A1 (en) | 1990-12-17 | 1992-06-24 | F. Hoffmann-La Roche Ag | Benzodiazepinones |
EP0558104A1 (en) | 1992-01-21 | 1993-09-01 | GLAXO S.p.A. | 1,5-Benzodiazepine derivatives and their use in medicine |
US5610158A (en) | 1992-02-13 | 1997-03-11 | The Upjohn Company | 4-oxo- and 4H-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents |
US5658901A (en) | 1994-08-18 | 1997-08-19 | Merck & Co., Inc. | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines |
EP1157992A1 (en) | 1994-08-31 | 2001-11-28 | Eli Lilly And Company | Dihydro-2,3-Benzodiazepine derivatives |
EP1593683A2 (en) | 1994-08-31 | 2005-11-09 | Eli Lilly And Company | Dihydro-2,3-Benzodiazepine derivatives |
EP0733634A1 (en) | 1995-03-24 | 1996-09-25 | Eli Lilly And Company | Process for preparing a thieno(2,3-B)(1,5) benzodiazepine derivative |
US20020103371A1 (en) | 2000-11-16 | 2002-08-01 | Raffaello Masciadri | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives |
US20040157833A1 (en) | 2002-12-03 | 2004-08-12 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1- (3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP2487174A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9284331B2 (en) | 2012-08-23 | 2016-03-15 | Novartis Ag | Diazepinone derivatives |
US9650377B2 (en) | 2012-08-23 | 2017-05-16 | Novartis Ag | Diazepinone derivatives |
WO2021139843A2 (es) | 2019-12-26 | 2021-07-15 | Centro de Investigación Y Desarrollo de Medicamentos CIDEM | Composición y método de tratamiento para simultáneamente incrementar la eficacia analgésica de los opioides y reducir su poder adictivo |
Also Published As
Publication number | Publication date |
---|---|
US20120202791A1 (en) | 2012-08-09 |
JP2013507329A (ja) | 2013-03-04 |
CU20090172A7 (es) | 2011-10-05 |
EP2487174A4 (en) | 2013-05-08 |
EP2487174A2 (en) | 2012-08-15 |
US10138231B2 (en) | 2018-11-27 |
US9315497B2 (en) | 2016-04-19 |
CN102656171A (zh) | 2012-09-05 |
CA2777209C (en) | 2016-11-22 |
US20190092769A1 (en) | 2019-03-28 |
ZA201203295B (en) | 2014-10-29 |
CA2777209A1 (en) | 2011-04-14 |
KR20120093940A (ko) | 2012-08-23 |
WO2011041989A3 (es) | 2011-09-15 |
US20140275042A1 (en) | 2014-09-18 |
CU20090172A6 (es) | 2011-10-05 |
CU23879B1 (es) | 2013-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011041989A2 (es) | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular | |
JP2023075159A (ja) | 有機化合物 | |
Taylor et al. | Synthesis of Pyrrolo [2, 3-d] pyrimidines. The Aglycone of Toyocamycin1, 2 | |
JP7290638B2 (ja) | Wee1阻害剤としての大環状化合物及びその使用 | |
Mathew et al. | Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors | |
CN105518005A (zh) | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 | |
AU718748B2 (en) | AZA and AZA (N-oxy) analogs of glycine/NMDA receptor antagonists | |
KR20090130319A (ko) | 스피로인돌리논 유도체 | |
Shankaraiah et al. | Synthesis of novel C3-linked β-carboline-pyridine derivatives employing khronke reaction: DNA-binding ability and molecular modeling studies | |
PT1953161E (pt) | Novos derivados tricíclicos, processo para a sua preparação e composições farmacêuticas que os contenham | |
KR20180049056A (ko) | 삼환식 축합피리딘-2-온 유도체 및 이들의 brd4 저해제로서의 용도 | |
JPS6019788A (ja) | アリ−ル又はヘテロアリ−ル〔7−(アリ−ル又はヘテロアリ−ル)ピラゾロ〔1,5−a〕ピリミジン−3−イル〕メタノンおよびその製造法 | |
CA2730071A1 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
PT95526A (pt) | Processo para a preparacao de derivados de 10,5-(iminometano)-5h-dibenzo{a,d}ciclo-hepteno uteis como agentes neuroprotectores | |
Che et al. | Synthesis of chiral 2-(2′-pyrrolidinyl) pyridines from (S)-and (R)-proline: potential ligands of the neuronal nicotinic acetylcholine receptors | |
Kafka et al. | The first entry to pyrrolo [2, 3-c] quinoline-2, 4 (3aH, 5H)-diones | |
JPS61204186A (ja) | ピリダジノピロロイソキノリン誘導体 | |
KR20080083194A (ko) | 이미다조[1,2-α]피리딘-3-일-아세트 산 하이드라자이드,이들의 제조 방법 및 이들의 용도 | |
DK168214B1 (da) | 3-acylaminomethyl-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridinderivater, fremgangsmåde til fremstilling af og lægemiddel indeholdende sådanne derivater | |
JP2006507269A (ja) | ピロロ[3,4−c]カルバゾールおよびピリド[2,3−b]ピロロ[3,4−e]インドール誘導体、その製造法、ならびにそれを含有する医薬組成物 | |
Reddy et al. | Facile synthesis of 4-((5-substituted-1H-indol-3-yl) methyl)-3-methyl-1-phenyl-1H-pyrazol-5-ols by selective reduction | |
DE2016268C3 (de) | (4aRS, 5SR, 9bSR)- und (4aRS, 5SR, 9bRS) -13,4,4a3,9b-Hexahydro-5-phenyl2H-indeno [Uc] pyridine, ihre Salze, Verfahren zu ihrer Herstellung und Arzneimittel | |
JPH07500571A (ja) | Pcpレセプター・リガンドおよびその用途 | |
Matzen et al. | Bioisosterically modified dipeptide excitatory amino acid receptor antagonists containing 3-oxygenated isothiazole ring systems | |
HU191548B (en) | Process for the production of 1-cyclohexyl-3,4-dihydro-iziquinoline-derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080055659.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13500983 Country of ref document: US Ref document number: 2012532450 Country of ref document: JP |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2777209 Country of ref document: CA |
|
ENP | Entry into the national phase in: |
Ref document number: 20127011917 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4089/DELNP/2012 Country of ref document: IN Ref document number: 2010821598 Country of ref document: EP |